Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Rituximab, Eltrombopag, and Dexamethasone for Frontline ITP
NCT02834286Phase 2Unknown
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Mar 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and eltrombopag in immune thrombocytopenia (ITP), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Primary endpoint: Clinical Response at 28 days. Status: unknown.
02
Drugs
rituximabeltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02834286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834286.